Back to all news
Macro Finance

Sellas Life Sciences Surges 156% After Cancer Vaccine Data

Bloomberg Markets·November 17, 2026·1 min read

Sellas Life Sciences Group Inc. surged 156% after the drug developer reported positive late-stage trial results for an experimental cancer vaccine targeting an aggressive form of blood cancer. The data marks a significant milestone for the company, boosting investor confidence in its pipeline.

Read at Bloomberg Markets
Daily crypto arcade

Read the news, then play it.

Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.

Open ChainshortsGet it on the Solana dApp Store